Vilya By Rick Morgan – Inno Senior Reporter, Puget Sound Business Journal Jun 10, 2024 Preview this article 1 min ...

Vilya last year hired biotech vet Cyrus Harmon as its CEO. Harmon previously co-founded and led Olema Oncology. Vilya has 40 employees, with about a quarter in the Seattle region.

SEATTLE, June 04, 2024 (GLOBE NEWSWIRE) -- VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, announced today an expanded $71 ...

Courtesy of Vilya By Ron Leuty – Senior Reporter, San Francisco Business Times Jun 4, 2024 Preview this article 1 min ...

Vilya, an IPD spinout company, uses its proprietary platform combining novel algorithms with an understanding of uncharted chemical space to design new molecular structures not found in nature.

Vilya’s ability to precisely design membrane permeable molecules with high structural accuracy opens the door to a new class of medicines that combine the advantages of traditional small ...

Vilya says it will license the platform and molecules described in the Cell research paper, and has raised $50 million in Series A financing from a group of investors led by Arch Venture Partners.

Vilya formally launched in August 2022 with Moyer, Hiranuma, and Salveson on staff. In contrast with linear peptides, which are lines of amino acids, macrocyclic peptides have amino acids arranged ...

– License of proprietary RFdiffusion-based model, RFpeptides, provides Vilya with another powerful structure prediction framework for rapid and unique design of potent and selective macrocycles ...